PL
Przedmiotem badań było 100 ESBL-dodatnich szczepów Gram-ujemnych pałeczek wyizolowanych z przypadków zakażeń u hospitalizowanych pacjentów. Oznaczono wrażliwość in vitro tych szczepów na cefalosporynç IV generacji - cefepim. Zastosowano gradientowo-dyfuzyjną metodę Etest. Wśród badanych szczepów 14 bylo wrażliwych, 12 - średniowrażliwych i 74 - opornych na cefepim.
EN
The aim of this study was to determine an in vitro activity of cefepime against ESBL-positive clinical strains of Gram-negative rods isolated from hospitalized patients. Experiments were performed with 100 ESBL-positive strains of Gram-negative rods isolated from clinical samples in 2004. Strains were identified with the use of automatic ATB Expression system and biochemical ID 32 GN tests (bioMérieux® sa). Extended-spectrum beta-lactamases (ESBLs) were detected by means of disc diffusion methods: the double-disc synergy test (DDST) and the diagnostic disc test (DD, Oxoid Ltd, UK). Susceptibility in vitro of ESBL producers to 4th generation - cefepime was determined with gradient diffusion method Etest (AB Biodisk, Solna, Sweden). MIC value of cefepime was assessed for each strain. Among 100 ESBL-producing strains, 94 - belonged to enteric rods and б - to nonfermentative rods. The greatest number of strains belonged to the species Serratia marcescens (27% of all strains) and next - to the species Enterobacter cloacae (21%). Fourteen strains were susceptible (S) in vitro to cefepime, 12 - intermediately susceptible (I) and 74 - resistant (R). Application of cefepime in a therapy of infections caused by ESBL-positive strains of Gram- negative rods highly susceptible in vitro to this antibiotic, should be considered.